Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

10.38 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Navigating 5 Analyst Ratings For Arcus Biosciences
 
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
 
Via Benzinga
Recap: Arcus Biosciences Q4 Earnings
 
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Preview: Arcus Biosciences's Earnings
 
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
Key Takeaways From Arcus Biosciences Analyst Ratings
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Arcus Biosciences
 
Via Benzinga
Arcus Biosciences: Q3 Earnings Insights
 
Via Benzinga
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today! 
Via InvestorPlace
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy. 
Via Benzinga
Gilead and Arcus Announce Amended Collaboration and Equity Investment
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
From laggards to leaders: Small caps on the rise
Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains. 
Via MarketBeat
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month... 
Via Benzinga
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback